HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U.S. beauty growth

This article was originally published in The Rose Sheet

Executive Summary

The demand for cosmetic and toiletry chemicals in the U.S. is expected to rise 5.4% per year to $7.6 bil. in 2010, according to industry research company The Freedonia Group. The growth will be driven by favorable trends in demographics as well as "consumer desires to offset the effects of aging, and preferences for 'natural'" products, the Cleveland-based company says. As a result, "active and plant-derived ingredients will benefit the most," firm adds. Growing demand for active ingredients, such as amino acids and peptides, "will be propelled by continued gains in cosmeceuctical skin care products and high-value additives such as nanoscale ingredients," firm reports. Male grooming, ethnic products, anti-aging and products for consumers 50+ are poised to achieve "rapid" growth through 2010...

You may also be interested in...



Male Grooming Promos Capture Webby Award Nominations

Nominees for the 11 Annual Webby Awards' Best Beauty and Cosmetics Site of the Year highlight the creativity of online promotions targeting young men

As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure

The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014080

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel